Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02402036 · ClinicalTrials.gov registry record · Phase 2
A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02402036 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 10 participants.
The verdict
NCT02402036, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an exploratory biomarker study. Patients with metastatic colorectal cancer will receive regorafenib, which is FDA approved in this setting, on day 1-21 of every consecutive 28 day cycle. Patients will be asked to undergo tumor biopsy at baseline and 2 weeks after starting regorafenib. Peripheral blood samples will be collected at baseline 2 weeks after starting regorafenib, after initiation of cycle 3, and every 4 weeks thereafter.
Interventions
- DRUG Regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02402036
The ClinicalTrials.gov registry entry for NCT02402036 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regorafenib is the first listed.
NCT02402036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02402036 about?
NCT02402036 is a clinical study titled "A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer". This is an exploratory biomarker study. Patients with metastatic colorectal cancer will receive regorafenib, which is FDA approved in this setting, on day 1-21 of every consecutive 28 day cycle. Patients will be asked to undergo tumor biopsy at baseline and 2 weeks after starting regorafenib. Periph...
What is the current status of trial NCT02402036?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-02. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02402036?
The interventions under investigation include: Regorafenib (DRUG).
Who is sponsoring clinical trial NCT02402036?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.